<DOC>
	<DOCNO>NCT00551473</DOCNO>
	<brief_summary>Current treatment gastroesophageal reflux disease ( GERD ) confirm unmet need patient , base slow onset action inability provide 24-hour gastric acid suppression . Clinical data lavoltidine demonstrate rapid onset action , high potency , prolonged duration effect single dose . Since tolerance class compound lavoltidine belongs may dose dependent , current study design determine 40mg lavoltdine give 7days develops tolerance .</brief_summary>
	<brief_title>Open-label Comparison 24hr Gastric pH Days 1 , 2 , 7 With Once-daily Administration Lavoltidine 40 mg .</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<criteria>Healthy male , 1855 year Have BMI 1930 kg/m2 present abnormal clinical lab finding able tolerate nasogastric pH electrode . Helicobacterpositive C13 urea breath test baseline median 24hour gastric pH &gt; 3</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>pharmacodynamics ,</keyword>
	<keyword>tolerance</keyword>
	<keyword>H2 antagonist ,</keyword>
	<keyword>AH23844 ,</keyword>
	<keyword>lavoltidine ,</keyword>
	<keyword>gastroesophageal reflux disease ( GERD ) , pharmacokinetics ,</keyword>
</DOC>